Explore /
Poster
/ Durvalumab (D) and PET-directed chemoradiation (CRT) after induction FOLFOX for esophageal adenocarcinoma: Final results.

Durvalumab (D) and PET-directed chemoradiation (CRT) after induction FOLFOX for esophageal adenocarcinoma: Final results.

Authors

Darren Cowzer

Department of Medicine, Memorial Sloan Kettering Cancer Center, New York, NY

Darren Cowzer , Abraham Jing-Ching Wu , Smita Sihag , Henry S. Walch , Bernard J. Park , David Randolph Jones , Ping Gu , Steven Brad Maron , Ryan Sugarman , Sree Bhavani Chalasani , Marina Shcherba , Marinela Capanu , Joanne F. Chou , Anton Nosov , Randy Yeh , Laura H. Tang , David H. Ilson , Yelena Y. Janjigian , Daniela Molena , Geoffrey Yuyat Ku

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

Poster Details

Meeting

2022 ASCO Annual Meeting

Session Type

Poster Session

Session Title

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Track

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Sub Track

Esophageal or Gastric Cancer

Clinical Trial Registration Number

NCT02962063

Citation

J Clin Oncol 40, 2022 (suppl 16; abstr 4029)

DOI

10.1200/JCO.2022.40.16_suppl.4029

Abstract #

4029

Poster Bd #

Abstract Disclosures

Similar Posters

Poster

2024 ASCO Gastrointestinal Cancers Symposium

Phase 1b/II study of durvalumab (D) and tremelimumab (T) plus PET-adjudicated chemoradiation (CRT) in patients (Pts) with esophageal adenocarcinoma.

First Author: Geoffrey Yuyat Ku

Poster

2020 Gastrointestinal Cancers Symposium